Financial Results for the Fiscal Year Ended March 31, 2026 (FY2025)

from the beginning

Financial Results for the Fiscal Year Ended March 31, 2026 (FY2025)

• Forward-Looking Statements and Use of Document

• Highlights

• P&L, FCF

• One-time Expenses / Adjustments

• OP Variance Analysis (Q4): Growth due to strong sales

• OP Variance Analysis (Q4 YTD): Contribution from pricing measures and strong sales

• C&V: TIS led the way, driven mainly by North America, TN also delivered growth

• TMCS: Increased sales in PS contributed to revenue and profit growth

• TBCT: GBS, including Plasma Innovation, drove revenue growth

• Terumo Organ Technologies: Rapid revenue growth by increasing liver transplants and market share

• Revenue by Region: Americas strongly drove overall growth

FY26 Guidance

• FY26 Guidance

• FY26 Guidance by Company

• Profit Variance Analysis (FY26 Guidance)

• Product and Regional Development

• Dividend Proposal: Continuous increase per shareholder return policy

References

• P&L (QoQ)

• SG&A (QoQ)

• SG&A (YoY)

• Adjusted Operating Profit: Adjustments

• CAPEX, Depreciation and Amortization, R&D Expenses

• Free Cash Flow

• Cash Flow（Q4）

• Cash Flow (Q4 YTD)

• Foreign Exchange Sensitivity

@

GS26 Final Year and Beyond ＆ Terumo Neuro Growth Roadmap

• Forward-Looking Statements and Use of Document

• Achieve All GS26 Financial Targets

• Key Growth Drivers for FY26

Terumo Neuro (TN) Growth Roadmap

• Executive Summary

• Overview of Neurovascular Business

• History of Neurovascular Business

• TN Sales Trends and Breakdown

• TN Growth Strategy

• Key Strength of TN: Integration and Iterations on Technology

• Key Strength of TN: Clinical Evidence Generation

• Growth Opportunities in Intrasaccular (WEB)

• Growth Opportunities in Ischemic (SOFIA)

• Operational Efficiency: Margin & Capacity Improvements

• Further Growth Opportunities in Adjacent Markets

• Future of TN

Next Growth Stage

• Toward GS31

@